Contact this trialFirst, we need to learn more about you.
PD-L1 Inhibitor
Durvalumab + Radiation for Lung Cancer
Recruiting1 awardPhase 2
Montvale, New Jersey
This trial is testing whether combining the drug durvalumab with a precise radiation treatment is more effective for early-stage lung cancer patients than using the radiation treatment alone. Durvalumab has shown promise in improving survival rates in advanced lung cancer patients and is being tested in various combinations, including with radiation therapy.
Fill-in a few details and create your profileSave answers to your profile & unlock recommendations.
We will keep your details privateWe won't share unless you give us permission. By completing this form you agree to our privacy policy and terms of service
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.
By clicking start, you agree to our
terms of service